Compare Mesoblast Limited (MESO) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

SOXS, the Direxion Daily Semiconductor Bear 3X ETF, is trading at $39.97, down 11.59% in the past 24 hours amid a bearish technical signal. The ETF benefits from recent semiconductor sector weakness, with news highlighting its surge during chip stock sell-offs. A 1:10 stock split is scheduled for July 26, 2026, while technical indicators show oversold conditions with RSI at 26.30.

The outlook remains volatile, with SOXS positioned to gain from continued semiconductor sector pressure, though leveraged inverse exposure carries high risk. Key risks include rapid AI-driven chip rallies reversing bearish bets. Investors should weigh sector volatility against the ETF's structure, with support at $41 and resistance at $45.